Sven Lee: How Terumo BCT are unlocking the potential of blood.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Sven Lee: How Terumo BCT are unlocking the potential of blood.
Released on: August 26, 2015. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Terumo BCT, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing.
  • Summary
  • Transcript
  • Participants
Terumo BCT, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. During the World Stem Cell Congress, Sven Lee, Director of Global Sales and BD at Terumo BCT talked to Adrian Dawkes, VP at PharmaVentures about the collaborations they are involved in and the challenges faced in the field of regenerative medicine.
Terumo BCT, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. During the World Stem Cell Congress, Sven Lee, Director of Global Sales and BD at Terumo BCT talked to Adrian Dawkes, VP at PharmaVentures about the collaborations they are involved in and the challenges faced in the field of regenerative medicine.
Terumo BCT